The 5-year survival rate is only about 5%. NEK8 is involved in multiple biological processes in a variety of cancers; however, its role in glioma is still not clear. In the current study, we evaluated the prognostic value of NEK8, as well as its role in the pathogenesis of glioma. ...
(5-yearsurvival rateof 5%), while patients with anaplastic astrocytomas have aMSTof 2 to 5 years (5-year survival rate of 30%) (Wen and Kesari, 2008;Goodenberger and Jenkins, 2012). The progression to high-grade gliomas is common among patients with lower-grade tumours (Perry and ...
For the more aggressive form of glioma, glioblastoma, the survival rate with 5-year lifespan from the time of diagnosis is less than 5% (Stupp et al., 2005). Hence, glioma is considered as a malignant tumor and characterized by rapid growth, strong invasiveness, frequent postoperative relapse...
five times (N = 5 mice per group/experiment). Sections were counterstained with hematoxylin (blue). Scale bar, 2 mm; inset scale bar, 25 µm.dKaplan–Meier survival curve of animals bearing U87-control (N = 14), IL-33 (clone 3,N = 10; clone 9,N = 10)...
Glioblastoma is a highly aggressive and malignant type of brain cancer that originates from glial cells in the brain, with a median survival time of 15 months and a 5-year survival rate of less than 5%. Regulated cell death (RCD) is the autonomous a
In addition to PFS and time to next intervention, the study is assessing the ORR of vorasidenib, overall survival, tumor growth rate, safety/tolerability, health-related quality-of-life (HRQOL) by Functional Assessment of Cancer Therapy-Brain Questionnaire, and plasma pharmacokinetics as second...
Lactate has emerged as a critical regulator within the tumor microenvironment, including glioma. However, the precise mechanisms underlying how lactate influences the communication between tumor cells and tumor-associated macrophages (TAMs), the most abu
Vorasidenib(AG-881) monotherapy elicited a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with placebo in patients with residual or recurrent IDH1/2-mutant low-grade glioma, meeting the primary end point of the phase 3 INDIGO trial (NCT04164...
The 5-year overall survival rate of patients is less than ten percent.3 To date, the molecular mechanism involved in the development of glioma remains unclear. Therefore, it is necessary to develop new therapeutic strategies and improve the clinical outcome. In recent decades, microRNAs (miRNAs)...
With an age-adjusted incidence rate of 4.15 per 100.000 person years, high-grade gliomas represent 21.6% of all reported brain tumors in the US (CBTRUS, 2004–2007). The five year survival of a patient with a glioblastoma is 9.8% (6.4–14) and the median survival is 14.6 months (95% ...